Screener
ImmunityBio, Inc. IBRX Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other revenues | 39 | 8 |
| Total revenue | 44,206 | 16,517 |
| Operating costs and expenses | ||
| Cost of sales | 238 | 58 |
| Research and development | 64,770 | 45,976 |
| Research and development – related parties | 3,219 | 2,258 |
| Selling, general and administrative | 44,461 | 31,977 |
| Selling, general and administrative – related parties | 1,309 | 677 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total cost of revenue?
- ImmunityBio, Inc. (IBRX) reported total cost of revenue of $238K in Q1 2026.
- How has ImmunityBio, Inc.'s total cost of revenue changed year-over-year?
- ImmunityBio, Inc.'s total cost of revenue increased by 310.3% year-over-year, from $58K to $238K.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about ImmunityBio, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude